Allogeneic anti-CD19/BCMA CAR-T
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Allogeneic anti-CD19/BCMA CAR-T, covering 2026-01-05 to 2026-01-05. Get the full timeline:
Most recent: Clinical Trial Update: Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease [EARLY_Phase 1]